ARTICLE | Company News
Alfacell, Novartis deal
July 25, 2005 7:00 AM UTC
NVS's Novartis Institute for Tropical Diseases received rights to evaluate the activity of ACEL's AC 03-636 to treat Dengue fever. The compound is a ribonuclease antiviral. ...
Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
NVS's Novartis Institute for Tropical Diseases received rights to evaluate the activity of ACEL's AC 03-636 to treat Dengue fever. The compound is a ribonuclease antiviral. ...